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If we believe, as many of us do, that the industtywill indeed
realize significant future sales of biotechnology products, we
can then place a future value on these biotechnology companies in the conventional way in which we evaluate any industty
group, such as the major pharmaceutical and drug sectors. We
assume that not all future biotechnology product sales will be
by these up-start start-ups-perhaps 50% would be a fair
estimate. The balance of biotechnology product sales would
be by the multi- national pharmaceutical and drug companies.
Remember also that these large companies are acquiring, or
investing in, these small biotechnology companies.
Another point should be made. Although new biotechnology companies will continue to start-up to exploit niche
markets and specific product opportunity areas, the mainstream of biotechnology companies will already have been
established in the markets and new entries will be few. It is
expected that fully 2/ 3 of the companies presently in business
today will be gone in 10 years-some will fail , many will be
acquired by others. As a result, a smaller number of companies
will cut up the biotechnology pie in the future markets.
The market value of the biotechnology companies (today
$9 billion) may possibly be $100 bill ion in the year 2000- but
divided among considerably fewer players. Assuming 50 biotechnology companies remain at that time, the average market
value of each company would be $2 billion-a 20-fold
increase over the average market value today.

Investment Strategies
Before reaching for your checkbook to make an investment
in biotechnology today, understand that any number of
assumptions can be made and any number of differing results
may be suggested. An investment today in evety one of the
biotechnology companies held until the year 2000, quite
assuredly will not realize the 20-fold average increase suggested above. Even if the industty values came true in that
year, dilution of the investment interests by the significant
additions to equity capital that may be necessary along the way
would change the returns. And how much is won or lost in
those companies that are acquired or go out of business is
anyone's guess.
The hint of signficant values in biotechnology, however, is
realistic. It may require considerable patience, some anguish,
and a lot of luck, however, to realize your investment return
dream in biotechnology.
The typical investment strategies can be suggested. This
assumes considerable diligence on your part, a lot of sound
advice from others, and a long-term investment posture.
Invest in those undervalued biotechnology companies that
have significant technologies and markets, excellent management, considerable capital, several corporate partner relationships, and various sales and marketing agreements that
will result in significant growth in sales and earnings.
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Until comparatively recently, biotechnology has been a
subject of intense interest to a relatively narrow audience,
namely, to that segment of the scientific community working
at the leading edge of this "new biology." While there has
been a growing amount of communication in the lay press of
the progress and implications of biotechnology, attempts to
convey the significance of recombinant DNA, monoclonal
antibodies, hybridoma cells, and DNA probes have been a bit
bewildering to the general reader. This bewilderment has
only been compounded by discussions of high-potential new
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products with esoteric sounding names and strange sets of
initials ; e.g. , tissue plasminogen activator (TPA) , tissue necrosis factor (TNF), colony stimulating factor ( CSF), epidermal
growth factor (EGF), angiogenesis inhibitor, and Factor VIII,
being pursued by a great number of new companies with
confusingly similar names such as Genentech, Genex, Integrated Genetics, Plant Genetics, Molecular Genetics, Biogen,
Amgen, and Calgene. Excitement has nonetheless grown as
the potential to employ this technology and these substances
to treat diseases such as cancer, AIDS, and cardiovascular
Journal of the Minnesota Academy of Science

disease has come into increasingly sharp focus. Along with
this increasing awareness of a major new technology and
major new business in the making, has come a growth in
interest in the corresponding investment opportunities available.
While it is always dangerous to make dogmatic assertions,
there can be no doubt that biotechnology is destined to be big
business. The products of this technology will revolutionize
agricultural, veterinary, healthcare, chemical, energy, and
waste management businesses, to name a few. However,
while one can make a safe bet on this proposition, it does not
follow that equally certain investment returns will result from
a bet on any particular participant, or group of participants, in
this emerging industry. The technology is very dynamic, and is
being pursued by a large and growing number of companies.
Some of these companies will fail , others will succeed-either
on their own or by virtue of being acquired by others. In
targeting particular companies as investment options, one
needs to make judgments about company management,
financial underpinning, technology, markets, marketing capability, manufacturing capability, patent position, regulatory
requirements, competition, and strength of corporate
partners. Even if one appropriately judges this multiplicity of
key success factors and identifies a number of companies
which, in fact, ultimately emerge as business successes, an
investment in the common stock of one or more of these
companies could still bring the investor to grief.
In making common stock investments, it is important to
view the stock as having a life of its own apart from the health
and life of the underlying business. Thus, a company's business may be doing very well, with excellent prospects for
future sales and profit growth. Investors, sensing these prospects, will generally bid the stock of such a company to levels
at which an acceptable investment return is difficult to
achieve. Subsequent reports of sales and earnings progress
may be greatly improved over prior periods, but because such
progress is less than anticipated, the stock declines in price.
Conversely, a company's business may be experiencing some
temporary hard times. But because investors are not certain
whether, in fact, such times are temporary, or, even if temporary, how severe the hard times will be, the stock may be selling
at such a discount to "fair value" that an investment made in
the company's common stock yields excellent returns. Subsequent financial reports may show that the hard times are over
sooner than expected and/ or are less severe than anticipated,
leading to a price rise in the common stock. Thus, it often
happens that when a company's business looks the worst, the
common stock is at a price that subsequently proves to have
been very attractive. Yet, this is also the point at which the
psychological frame of mind of most investors is least disposed to undertake investment risk. Again, it is important at
any point to make separate judgments about the business and
the stock. They do not often move in lockstep.
The importance of rigorously separating the judgment of
business prospects from that of stock valuation is even more
important in the case of biotechnology, an emerging industry
populated with emerging growth companies. Few of these
companies have any significant product revenue at this point,
and even fewer-you can count them on one hand-are
profitable. The stocks of these companies tend to be "expectations" driven and "key milestone achievement" driven, rather
than current, or even near-term, earnings driven. Since expectations are frequently limited by very little more than our
imaginations (or our greed), the stock of a company investigating a cancer cure, or an AIDS vaccine, or an agent to abort
heart attacks, is frequently bid up to levels difficult to mainVolume 53, Number 1, 1987/ 88

tain, or justify, even in the face of progress towards the
expected goal.
I will attempt to illustrate my point with an example. Amgen
is considered to be one of the premier biotechnology companies, one of the elite group of biotechnology companies
voted by most knowledgeable observers as "most likely to
succeed," a judgment with which I have absolutely no reason
to disagree. As this is written, Amgen common stock is selling
at $37 per share and the company has 16.3 million shares
outstanding. In fiscal1986, the company had $23.4 million in
total revenue-$20.2 million from corporate partners in support of Amgen R&D programs, $2.3 million in interest income
from its cash, and a mere $0.86 million in product revenue.
The company was profitable, earning $548,000, or $0.05 per
share, although it clearly would not have been had it relied on
profitable operations stemming from product revenue. I do
not follow the company closely, but the consensus earnings
estimate of 12 analysts who do, is that the company will earn
$0.08 per share in fiscal1987 . Thus, the stock is selling at 463
times 1987 earnings. Considering that the overall market is
currently selling at 15-16 times anticipated 1987 earnings, the
current price of Amgen stock incorporates a considerable
measure of assumed future success. As the industry and
Amgen matures, this earnings multiple is going to decline.
Let's just assume for the moment that Amgen was currently a
solidly established business, with good, and growing, revenue
and profits. Where should the company be in terms of revenue
and profits to justify a multiple of 25 times earnings, still a
near-70% premium to the market? Since the stock is selling at
$37, a multiple of25 times earnings would imply earnings of
37/ 25, or $1.48 per share. Given that the company currently
has 16.3 million shares outstanding, $1.48 per share would
dictate $24.1 million in net income. If we then assume that this
net income amounts to a generous 15% of revenue, revenue
would need to be more than $160 million, considerably
greater than the $0.86 million achieved in fiscal 1986.
I would emphasize that the point of this example is not that
Amgen will never achieve $160 million in revenue; I have
every reason to believe that it will. It is also not the point that
Amgen common stock is not a good buy; I suspect that it will
prove to be a good investment, particularly for investors who
approach investing in such situations appropriately, a subject I
will return to in a moment. Rather the point is that the prices of
the expectations-driven stocks of emerging growth companies are subject to continuous, and frequently substantial, readjustment, reflecting investor reaction to the real or imagined
impact of events on the previously assumed level of ultimate
success. Some of these events will be completely beyond the
company's control as, for example, a time of overall reduced
interest in the biotechnology sector of the market; a pronounced overall bear market, wherein it is difficult for the
stocks of any company to do well regardless of progress or
prospects; the entrance of a competitor into the same markets;
or a delay in receiving necessary regulatory approval for a
.product. Any such events can lead investors to be, at least
momentarily, less optimistic and less willing to pay the same
price for the stock. The bottom line result with respect to
investors is that emerging growth stocks tend to be highly
volatile. Investors, particularly individual investors, frequently
do poorly in such stocks because they lose their nerve and the
courage of their convictions, selling out their positions at a
loss. As mentioned earlier, this is frequently the time at which
such stocks should be bought. Not always, however!
If it seems that I am making every effort to scare potential
biotechnology investors, let me emphasize my belief that
excellent returns are available to investors who invest wisely
37

in this area. Since most people grasp very quickly the concept
of exceptional return, but less quickly the concept of commensurate exceptional risk-and risk and return do go hand
in hand-I intentionally spend more time discussing risk.
How should a person go about approaching investments in
the biotechnology area, and what are the options? The first
rule, important in any stock market investing, but particularly
important with emerging growth stock investing, is not to
venture any money that you cannot afford to have experience
substantial erosion. As mentioned, growth stocks generally
evince considerable volatility. Hence, you should not invest
$5,000 absolutely needed six months from now for a child's
college tuition payment. While the $5,000 could appreciate to
$10,000 three years from now, it could just as easily depreciate
to $2,500 in six months' time. While this first point is a rule, the
second point is a suggestion. The suggestion is that once you
have done adequate research to determine that the stock of
"Biotech Company X" is an attractive buy, determine how
much money you are prepared to invest/ risk, then commit
some fraction of that, say 1/ 3 or 1/2. Then resolve to commit
the other half (or another third as the case may be) when and
if the price goes against you by a predetermined amount. If the
stock moves up and away from you, be satisfied with how
smart you were, rather than despairing over not having committed everything originally. If events subsequent to your
original investment provide added confirmation for your
assessment of the business and the stock, buy more stock at
higher prices. If, on the other hand, the stock declines to your
predetermined price points, and you are confident that the
rationale for making your original investment is still intact,
buy some more stock and average down in anticipation of the
upward price move you expect. So much for strategy. What are
the investment options?
One investment option is to buy the stock of a "pure play"
biotechnology company, a company whose future success is
entirely dependent on its commitment to biotechnology.
Depending on how you choose to count and characterize
biotechnology companies, there are now at least 50 with
publicly traded stock, with many others that are likely to come
public in the days ahead. Many of these companies are nearly
totally dedicated to therapeutic or pharmaceutical applications of biotechnology, others to diagnostic applications,
some to agricultural and/ or veterinary applications, and still
others to chemical, energy, or other industrial applications.
Some companies have strong commitments to more than one
of these areas of application. A partial, and clearly incomplete,
list of companies considered to be at the forefront of their
particular areas would include Amgen, Calgene, Centocor,
Cetus, Chiron, Genentech, Genetics Institute, and Integrated
Genetics. Sources of information on companies of interest
would include the recent annual reports and quarterly reports
(readily obtainable directly from the investor relations
department of the company), analyst reports on the company
(obtainable through a brokerage firm), and a good business
library such as the JJ. Hill Reference Library in St. Paul. Such
libraries generally contain numerous investment resources
including The Wall Street Transcript, which carries a lengthy
"Roundtable" discussion of the biotechnology industry at
least once a year.
The so-called "pure play" investment option carries the
potential for the greatest -even spectacular -returns of any of
the investment options to be discussed, assuming one "bets
on the right horse." This option also carries the potential of
the greatest- approaching total-loss, if you select poorly.
The "pure play, all the eggs in one basket" approach entails
both the prospects of exceptional return and exceptional risk.
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A second approach would be to attempt to reduce potential
risk, although at the same time reducing potential return, by
taking an individual diversification approach. That is to say,
rather than investing a given sum in one biotechnology stock,
invest, for example, one-third of that sum in each of three
biotechnology stocks. Assuming that you have done reasonably good homework, it is not likely that all the selections will
perform dismally, although it is also unlikely that all will
perform spectacularly. One excellent choice can still mask the
"sins" of two poor to mediocre performers, yielding overall
good investment returns. You should stay mindful that while
this individual diversification approach can insulate you
somewhat from issue-specific investment risk, it does not
provide protection from overall market risk. As mentioned
earlier, it is difficult to find any stocks that go up in the midst of
a strong overall bear market. In fact , in such a market, emerging growth stocks with high levels of assumed future success
incorporated into their stock prices tend to be the most
vulnerable.
A third biotechnology investment option would be what
can be called the "single stock diversification" approach. What
is suggested here is to select common stocks of companies
that are successfully established in existing businesses but
that seek to enlarge those businesses or to establish new
businesses through the application ofbiotechnology. Illustrative examples could include Abbott laboratories, Eli Lilly,
Bristol-Myers, Merck, Syntex, Johnson & Johnson, Becton
Dickinson, and (surprise!) Eastman Kodak.
The so-called single stock diversification approach would
be expected to reduce risk significantly. In the case of Abbott
laboratories, for example, this company is clearly well established, a near "blue chip," with leadership positions in pharmaceutical, diagnostic, and hospital supply businesses. Both
the Abbott business and the common stock have been solid
performers for years. The company is making substantial
investments in biotechnology, both within its own research
laboratories as well as through the support of research programs in the laboratories of various "pure play" biotechnology companies. Should this "drilling" for new biotech products strike a "dry hole," the base of solidly established
businesses with good performances would substantially
cushion the company and its investors. Conversely, a spectacularly successful new biotechnology product would not have
the same positive impact on the financial performance of an
Abbott Laboratories that it would have on a smaller, "pure
play" company. The financial impact on a company the size of
Abbott would be less, with a correspondingly reduced impact
on the price of the stock, as well as on investor return. Again, if
you insist on taking less risk, you should correspondingly
reduce your return expectations.
The fourth , and final , approach to investing in bi otechnology
is to turn over your money to a professional money manager
who is committed to investing in biotechnology stocks,
i.e., a biotechnology mutual fund. To a certain extent, this
particular option is more conceptual than real , since I am not
aware of the existence of a mutual fund devoted exclusively to
biotechnology. In time there probably will be. The closest you
would come would be through a fund such as the H&Q
Healthcare Investors Fund, a fund committed to investing
primarily in biotechnology, diagnostics, healthcare services,
and pharmaceutical stocks. If the diagnostics and pharmaceutical stocks selected for the Fund turn out to be companies
seeking to achieve their business objective through biotechnology, this could approximate a pure biotechnology fund. In
addition, this fund is committed to investing approximately
25% of its cash in venture capital situations, a very high return/
jo urnal of the Minnesota Academy of Science

high risk approach rarely available to most people on an
individual basis. The mutual fund approach offers a much
more diversified, risk-reduced approach than is achievable via
the previously mentioned individual diversification approach.
However, I would again emphasize that in a strong bear
market, even an investment in a large universe of stocks, each
of which is itself high risk, is vulnerable.
To summarize, efore choosing to invest in any common
stocks, but particularly volatile, potential high risk/ high
return, emerging growth stocks such as biotechnology stocks,
"know thyself. " Know what you are prepared to risk, and how
much risk you are prepared to take. Do not risk more than you
are prepared to lose. Second, do your homework. Third,
should you choose to invest in biotechnology stocks, choose
an approach, be it the "pure play" or the three forms of
diversification strategy, which most closely matches your risk
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tolerance, while bearing in mind that diversification among a
universe made up solely of high fisk stocks can only achieve
so much risk reduction ; a certain return with essentially zero
risk is obtainable only through U.S. Treasury bills. Fourth,
once you have committed your hard-earned cash to the
market, keep an open mind and a cool head-an open mind
ready, willing, and able to continuously assess the impact of
new information on original investment assumptions, and a
cool head able to stay with an originally determined investment strategy as long as no new contrary information has
come to light. Fifth, specific company names used during the
course of these remarks are not intended nor should they be
taken as investment recommendations, but rather as illustrative examples and as places to begin making your own
assessment.
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